Canaccord analyst William Plovanic lowered the firm’s price target on Boston Scientific (BSX) to $71 from $109 and keeps a Buy rating on the shares. The firm noted they reported inline Q1 results but guidance was lowered driven by Watchman, EP, and Urolgy struggles ahead.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target lowered to $85 from $90 at Truist
- Boston Scientific upgraded to Buy from Hold at Nephron Research
- Boston Scientific price target lowered to $78 from $86 at Baird
- Boston Scientific price target lowered to $75 from $94 at Wells Fargo
- Boston Scientific price target lowered to $96 from $100 at Barclays